SHAREHOLDER ALERT: Law firm Pomerantz is investigating claims on behalf of investors in BridgeBio Pharma, Inc.
NEW YORK, January 27, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors in BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529 ext. 7980.
The investigation focuses on whether BridgeBio and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.
[Click here for information about joining the class action]
At December 27, 2021, BridgeBio issued a press release “announcing[ing] Key results from Month 12 (Part A) of ATTRIbute-CM, an ongoing global Phase 3 study of acoramidis for the treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM). The BridgeBio press release revealed that the study failed to meet its primary endpoint.
At this news, the BridgeBio share price fell. $29.24 per share, or 71.98%, to close at $11.38 per share on December 27, 2021.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is recognized as one of the leading firms in the areas of corporate litigation, securities and antitrust. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he established, fighting for the rights of victims of securities fraud, breaches of fiduciary duty and corporate misconduct. The firm recovered numerous multimillion-dollar damages on behalf of class members. See www.pomlaw.com.
Robert S. Willoughby
888-476-6529 ext. 7980
SOURCE Pomerantz LLP